Drug intelligence / Profile preview

penpulimab + TP

Development stage: Preclinical
Lead developer: Kangfang Sainuo Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Penpulimab + TP appears to be a combination therapy consisting of penpulimab (a PD-1 inhibitor) and a chemotherapy regimen likely abbreviated as TP. Penpulimab is a humanized monoclonal antibody that targets the programmed death receptor-1 (PD-1), blocking its interaction with PD-L1 and PD-L2 to enhance T-cell-mediated immune responses against tumor cells. The TP component likely refers to a chemotherapy combination, possibly including paclitaxel and platinum-based agents (cisplatin or carboplatin).

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on penpulimab + TP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on penpulimab + TP.

Explore the full profile